Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming Sunday, April 14th, in Amsterdam.
He will describe the progress of the DNV3837 program, including new data and the design of the upcoming Phase II clinical trial in severe gastrointestinal infections caused by Clostridium difficile.
ECCMID is the world's premier Clinical Microbiology & Infectious Diseases event.
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients, announced that Georges GAUDRIAULT will give a presentation at the 29th Annual Congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID, Amsterdam, the Netherlands, from 13 April to 16 April).
He will introduce the DNV3837 antibiotic program at the Therapeutics pipeline corner which will be held on Sunday, April 14th, from 12:15 to 1:15pm. He will highlight new pre-clinical data and will provide information on the upcoming Phase II clinical study.
ECCMID is the world's premier Clinical Microbiology & Infectious Diseases event. It brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 12,000 colleagues. It will take place in Amsterdam, Netherlands, from 13 - 16 April 2019.
The details of the presentation will be disclosed at the end of the meeting.